AIRCHILL Investor Snapshot
AIRCHILL · Investor Snapshot · Last reviewed 15 August 2026
What exists today. What is still unproven. What the next round must de-risk.
Development-stage · TRL ≈ 4 · no CE mark · no FDA clearance · not for patient use · no established clinical benefit
Medical Cooling / AIRCHILL public development status
AIRCHILL is being developed as a transport-ventilation platform with controlled respiratory cooling for time-critical care. This page is the short first-read layer before the full investor data room.
The three questions first-time investors need answered
1. What exists today?
A physical laboratory demonstrator and a defined product concept; granted European and US patent rights; published and project-level mechanism/safety evidence; a public evidence, regulatory and market-access diligence layer.
2. What is not proven?
No AIRCHILL patient-efficacy dataset, no routine-use approval, no final design freeze, no completed QMS/certification package, no validated commercial adoption or reimbursement case, and no established clinical outcome benefit.
3. What does the next round finance?
The €7.5m planning round is designed around roughly 30 months of engineering, QMS/regulatory work, verification and validation, preclinical preparation and the path toward a planned first-in-patient feasibility gate in 2029.
Current financing frame
- Current round: €7.5m planning case
- Planned runway: 30 months
- Indicative follow-on after Gate B: €10–15m
- First-in-patient feasibility: planned for 2029
- Base-case commercial revenue through 2031: €0
- Planning values are assumptions, not commitments, forecasts or guarantees
What the public evidence supports
The public record supports continued investigation of the engineering and physiological mechanism and includes preclinical airway-safety work and limited human feasibility observations. Medical Cooling intentionally separates those findings from product-level clinical efficacy and patient-outcome claims.
The risks that should affect valuation and closing conditions
- Clinical benefit remains unproven; prior airway-cooling trials in the field are material risk context.
- The planned endotracheal product route must overcome the project’s own measured heat-transfer limitation associated with dead-space ventilation.
- EU Class IIb remains a planning assumption; US 510(k) versus De Novo remains to be tested through regulatory interaction.
- The granted patents are founder-controlled; assignment or an exclusive worldwide sublicensable licence to the operating company remains a defined financing step.
- Founder capacity, full-time leadership, QA/RA ownership and execution-team buildout require documentary de-risking.
- Customer discovery, signed LOIs, procurement validation and final pricing/unit economics are not represented as completed.
Next value-inflection gate
The immediate investment case is not based on assumed revenue. It is based on converting a TRL ≈ 4 development programme into a verified, controlled and regulator-ready product package with explicit stop/go criteria. The strongest next milestone is a completed bench, airway-safety and verification package that materially reduces product and regulatory uncertainty.
Diligence path
- Read the AIRCHILL product page for architecture, product scope and current status.
- Review the evidence page and research register for what is supported versus still hypothetical.
- Review regulatory and reimbursement assumptions separately from clinical claims.
- Use the Investor Data Room for the public document register, gaps and restricted-material map.
- Request transaction-sensitive documents only once investor fit is established.
AIRCHILL is a development-stage medical technology project. This page is for research, planning and investor-diligence orientation. It is not medical advice, a representation of regulatory approval, an offer of securities, an investment recommendation or a guarantee of future performance.